Compugen Ltd (CGEN) — 6-K Filings

6-K Filings (21)

• Compugen Sells Royalty Interest for $65M — Dec 17, 2025 Risk: low
  On December 16, 2025, Compugen Ltd. amended its license agreement with MedImmune Limited, a member of the AstraZeneca Group. Compugen sold a portion of its exis
• Compugen Ltd. Reports Q3 2025 Results — Nov 10, 2025 Risk: low
  Compugen Ltd. announced its third quarter 2025 financial results on November 10, 2025. The company is a foreign private issuer filing a Form 6-K report with the
• Compugen Ltd. Files Form 6-K with SEC — Oct 14, 2025 Risk: low
  On October 13, 2025, Compugen Ltd. issued a press release, which is being furnished as part of this Form 6-K filing. The press release is incorporated by refere
• Compugen Ltd. Holds 2025 Annual Shareholder Meeting — Sep 17, 2025 Risk: low
  Compugen Ltd. held its 2025 Annual General Meeting of Shareholders on September 16, 2025. The company previously filed the meeting notice, proxy statement, and
• Compugen Ltd. Reports Q2 2025 Results — Aug 6, 2025 Risk: low
  Compugen Ltd. reported its second quarter 2025 financial results on August 6, 2025. The filing is a Form 6-K, which is a report of a foreign private issuer. The
• Compugen Ltd. Files Form 6-K with Press Release — Jul 21, 2025 Risk: low
  On July 21, 2025, Compugen Ltd. announced the issuance of a press release, furnished as Exhibit 99.1 to this Form 6-K. The press release is incorporated by refe
• Compugen Ltd. Reports Q1 2025 Results — May 19, 2025 Risk: low
  Compugen Ltd. filed a Form 6-K on May 19, 2025, to report its first quarter 2025 financial results via a press release. The company, based in Holon, Israel, is
• Compugen Ltd. Files Form 6-K with Press Release — May 13, 2025 Risk: low
  On May 13, 2025, Compugen Ltd. issued a press release, furnished as Exhibit 99.1 to this Form 6-K. The press release is incorporated by reference into the Compa
• Compugen Ltd. Files Form 6-K with Press Release — Jan 8, 2025 Risk: low
  On January 8, 2025, Compugen Ltd. announced the issuance of a press release, furnished as Exhibit 99.1 to this Form 6-K filing. This report is being filed under
• Compugen Ltd. Files Form 6-K with Press Release — Nov 27, 2024 Risk: low
  On November 27, 2024, Compugen Ltd. announced the issuance of a press release, furnished as Exhibit 99.1 to this Form 6-K filing. This report is filed under the
• Compugen Ltd. Reports Q3 2024 Results — Nov 12, 2024 Risk: low
  Compugen Ltd. announced its third quarter 2024 financial results on November 12, 2024. The company, headquartered in Holon, Israel, is a biopharmaceutical compa
• Compugen Ltd. Files Form 6-K with Press Release — Nov 5, 2024 Risk: low
  On November 5, 2024, Compugen Ltd. announced the issuance of a press release, furnished as Exhibit 99.1 to its Form 6-K filing. This press release is incorporat
• Compugen Ltd. Holds 2024 Annual Shareholder Meeting — Sep 13, 2024 Risk: low
  Compugen Ltd. held its 2024 Annual General Meeting of Shareholders on September 12, 2024. The company previously filed the notice, proxy statement, and proxy ca
• Compugen Ltd. Reports Q2 2024 Results — Aug 6, 2024 Risk: low
  Compugen Ltd. reported its second quarter 2024 financial results on August 6, 2024. The filing, a Form 6-K, includes a press release detailing these results for
• Compugen Ltd. Schedules Annual Shareholder Meeting for Sept 12 — Aug 5, 2024 Risk: low
  Compugen Ltd. announced on or about August 5, 2024, that it is distributing its proxy statement to shareholders for an annual general meeting. The meeting is sc
• Compugen Ltd. Files Form 6-K for July 2024 — Jul 29, 2024 Risk: low
  On July 29, 2024, Compugen Ltd. announced the issuance of a press release, furnished as Exhibit 99.1 to this Form 6-K filing. This report is for the month of Ju
• Compugen Ltd. Files Form 6-K with SEC — May 30, 2024 Risk: low
  On May 30, 2024, Compugen Ltd. issued a press release, furnished as Exhibit 99.1 to this Form 6-K. The information in the press release, excluding the third par
• Compugen Ltd. Reports Q1 2024 Results — May 20, 2024 Risk: low
  Compugen Ltd. reported its first quarter 2024 results on May 20, 2024. The company, headquartered in Holon, Israel, is a biotechnology firm focused on biologica
• Compugen Appoints New CFO, David Silberman — May 15, 2024 Risk: low
  Compugen Ltd. announced on May 15, 2024, the appointment of David Silberman as its new Chief Financial Officer, effective August 15, 2024. He will succeed Alber
• Compugen Appoints Michelle Mahler, M.D. as Chief Medical Officer — Feb 15, 2024 Risk: low
  Compugen Ltd. announced on February 15, 2024, the appointment of Michelle Mahler, M.D., as its new Chief Medical Officer. Her appointment is effective March 1,
• Compugen Regains Nasdaq Compliance, Secures $10M AstraZeneca Milestone — Jan 8, 2024
  Compugen Ltd. announced on January 8, 2024, that it has regained compliance with Nasdaq's minimum bid price requirement, removing a significant delisting risk.

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX